{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:09:16Z","timestamp":1771474156665,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00705-023-05881-9","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T03:21:05Z","timestamp":1694748065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molnupiravir: an antiviral drug against COVID-19"],"prefix":"10.1007","volume":"168","author":[{"given":"Bhavarth","family":"Dave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kashvi C.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-0986","authenticated-orcid":false,"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranjal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palak","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"5881_CR1","doi-asserted-by":"crossref","unstructured":"Keni R, Alexander A, Nayak PG, Mudgal J, Nandakumar K (2020) COVID-19: Emergence, Spread, Possible Treatments, and Global Burden. 8","DOI":"10.3389\/fpubh.2020.00216"},{"issue":"1","key":"5881_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41182-020-00285-w","volume":"48","author":"T Girum","year":"2020","unstructured":"Girum T, Lentiro K, Geremew M, Migora B, Shewamare S (2020) Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review. Trop Med Health 48(1):1\u201315","journal-title":"Trop Med Health"},{"issue":"6","key":"5881_CR3","doi-asserted-by":"publisher","first-page":"102329","DOI":"10.1016\/j.dsx.2021.102329","volume":"15","author":"AK Singh","year":"2021","unstructured":"Singh AK, Singh A, Singh R, Misra A (2021) Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr 15(6):102329","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"5881_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA et al (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5(4):536\u2013544","journal-title":"Nat Microbiol"},{"issue":"18","key":"5881_CR5","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W-j Guan","year":"2020","unstructured":"Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708\u20131720","journal-title":"N Engl J Med"},{"issue":"4","key":"5881_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1128\/MMBR.69.4.635-664.2005","volume":"69","author":"SR Weiss","year":"2005","unstructured":"Weiss SR, Navas-Martin SJM (2005) Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69(4):635\u2013664","journal-title":"Microbiol Mol Biol Rev"},{"issue":"3","key":"5881_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/JCMA.0000000000000270","volume":"83","author":"Y-C Wu","year":"2020","unstructured":"Wu Y-C, Chen C-S, Chan Y-J (2020) The outbreak of COVID-19: An overview. J Chin Med association 83(3):217","journal-title":"J Chin Med association"},{"issue":"4","key":"5881_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jmv.25678","volume":"92","author":"H Lu","year":"2020","unstructured":"Lu H, Stratton CW, Tang YW (2020) Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 92(4):401\u2013402","journal-title":"J Med Virol"},{"issue":"87","key":"5881_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","volume":"728","author":"T Singhal","year":"2020","unstructured":"Singhal T (2020) A Review of Coronavirus Disease-2019 (COVID-19)2020. Indian J Pediatr 728(87):281\u2013286","journal-title":"Indian J Pediatr"},{"key":"5881_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3389\/fpubh.2020.596944","volume":"8","author":"N Haider","year":"2020","unstructured":"Haider N, Rothman-Ostrow P, Osman AY, Arruda LB, Macfarlane-Berry L, Elton L et al (2020) COVID-19\u2014zoonosis or emerging infectious disease? Front Public Health 8:763","journal-title":"Front Public Health"},{"issue":"1","key":"5881_CR11","first-page":"157","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91(1):157\u2013160","journal-title":"Acta Biomed"},{"issue":"7","key":"5881_CR12","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3201\/eid2607.200915","volume":"26","author":"A Kratzel","year":"2020","unstructured":"Kratzel A, Todt D, V\u2019kovski P, Steiner S, Gultom M, Thao TTN et al (2020) Inactivation of severe acute respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations and alcohols. Emerg Infect Dis 26(7):1592\u20131595","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"5881_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4103\/ijo.IJO_843_20","volume":"68","author":"RC Khanna","year":"2020","unstructured":"Khanna RC, Cicinelli MV, Gilbert SS, Honavar SG, Murthy GV (2020) COVID-19 pandemic: Lessons learned and future directions. Indian J Ophthalmol 68(5):703\u2013710","journal-title":"Indian J Ophthalmol"},{"issue":"1144","key":"5881_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/postgradmedj-2020-138386","volume":"97","author":"MT Adil","year":"2021","unstructured":"Adil MT, Rahman R, Whitelaw D, Jain V, Al-Taan O, Rashid F et al (2021) SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J 97(1144):110\u2013116","journal-title":"Postgrad Med J"},{"key":"5881_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/10408363.2020.1783198","volume":"17","author":"M Ciotti","year":"2020","unstructured":"Ciotti M, Ciccozzi M, Terrinoni A, Jiang W, Wang C (2020) Bernardini Ss. The Covid-19 Pandemic. Crit Rev Clin Lab Sci 17:365\u2013388","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"4","key":"5881_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020) The proximal origin of SARS-CoV-2. Nat Med 26(4):450\u2013452","journal-title":"Nat Med"},{"key":"5881_CR17","doi-asserted-by":"crossref","unstructured":"Tian L, Pang Z, Li M, Lou F, An X, Zhu S et al (2022) Molnupiravir and Its Antiviral Activity Against COVID-19. Front Immunol. 13","DOI":"10.3389\/fimmu.2022.855496"},{"key":"5881_CR18","doi-asserted-by":"crossref","unstructured":"Syed YY (2022) Molnupiravir: first approval. Drugs. 1\u20136","DOI":"10.1007\/s40265-023-01864-x"},{"issue":"6","key":"5881_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V et al (2022) Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 386(6):509\u2013520","journal-title":"N Engl J Med"},{"issue":"1147","key":"5881_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","volume":"97","author":"A Parasher","year":"2021","unstructured":"Parasher A (2021) COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 97(1147):312\u2013320","journal-title":"Postgrad Med J"},{"issue":"6","key":"5881_CR21","first-page":"737","volume":"13","author":"I Krynytska","year":"2021","unstructured":"Krynytska I, Marushchak M, Birchenko I, Dovgalyuk A, Tokarskyy O (2021) COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review). Iran J Microbiol 13(6):737\u2013747","journal-title":"Iran J Microbiol"},{"issue":"8","key":"5881_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782\u2013793","journal-title":"JAMA"},{"key":"5881_CR23","doi-asserted-by":"crossref","unstructured":"Liu L, Jing H, Wu X, Xiang M, Novakovic VA, Wang S et al (2022) The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. Front Cardiovasc Med. 9","DOI":"10.3389\/fcvm.2022.957006"},{"key":"5881_CR24","first-page":"654813","volume":"11","author":"GE Forcados","year":"2021","unstructured":"Forcados GE, Muhammad A, Oladipo OO, Makama S, Meseko CA (2021) Metabolic implications of oxidative stress and inflammatory process in SARS-CoV-2 pathogenesis: therapeutic potential of natural antioxidants. J Front Cell 11:654813","journal-title":"J Front Cell"},{"key":"5881_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-981-32-9366-3_5","volume":"2","author":"RK Thimmulappa","year":"2020","unstructured":"Thimmulappa RK, Chattopadhyay I, Rajasekaran S (2020) Oxidative stress mechanisms in the pathogenesis of environmental lung diseases. J Oxidative Stress in Lung Diseases 2:103\u2013137","journal-title":"J Oxidative Stress in Lung Diseases"},{"key":"5881_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s10930-020-09935-8","volume":"39","author":"S Suhail","year":"2020","unstructured":"Suhail S, Zajac J, Fossum C, Lowater H, McCracken C, Severson N et al (2020) Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: a review. J The protein journal 39:644\u2013656","journal-title":"J The protein journal"},{"issue":"9","key":"5881_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger F, Stiller C, Schmitzov\u00e1 J, Dienemann C, Kokic G, Hillen HS et al (2021) Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol 28(9):740\u2013746","journal-title":"Nat Struct Mol Biol"},{"issue":"7819","key":"5881_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"HS Hillen","year":"2020","unstructured":"Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P (2020) Structure of replicating SARS-CoV-2 polymerase. Nature 584(7819):154\u2013156","journal-title":"Nature"},{"issue":"1","key":"5881_CR29","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer RN, Ward AB (2019) Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 10(1):2342","journal-title":"Nat Commun"},{"issue":"1","key":"5881_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer RN, Ward AB (2019) Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 10(1):1\u20139","journal-title":"Nat Commun"},{"key":"5881_CR31","doi-asserted-by":"publisher","first-page":"112517","DOI":"10.1016\/j.biopha.2021.112517","volume":"146","author":"SMR Hashemian","year":"2022","unstructured":"Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H (2022) RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother 146:112517","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"5881_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.6026\/97320630017932","volume":"17","author":"SM Patil","year":"2021","unstructured":"Patil SM, Maruthi K, Bajpe SN, Vyshali V, Sushmitha S, Akhila C et al (2021) Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp). Bioinformation 17(11):932","journal-title":"Bioinformation"},{"key":"5881_CR33","doi-asserted-by":"crossref","unstructured":"Zarenezhad E, Marzi M (2022) Review on molnupiravir as a promising oral drug for the treatment of COVID-19. Med Chem Res. 1\u201312","DOI":"10.1007\/s00044-021-02841-3"},{"issue":"5","key":"5881_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2217\/fmb-2021-0252","volume":"17","author":"S Khiali","year":"2022","unstructured":"Khiali S, Khani E, Rouy B, Entezari-Maleki S (2022) Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. Fut Microbiol 17(5):377\u2013391","journal-title":"Fut Microbiol"},{"issue":"8","key":"5881_CR35","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.7326\/M22-0729","volume":"175","author":"MG Johnson","year":"2022","unstructured":"Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N et al (2022) Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial. Ann Intern Med 175(8):1126\u20131134","journal-title":"Ann Intern Med"},{"issue":"628","key":"5881_CR36","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","volume":"14","author":"WA Fischer","year":"2021","unstructured":"Fischer WA, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ et al (2021) A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med 14(628):eabl7430","journal-title":"Sci Transl Med"},{"issue":"541","key":"5881_CR37","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML et al (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12(541):eabb5883","journal-title":"Sci Transl Med"},{"issue":"1","key":"5881_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22580-8","volume":"12","author":"K Rosenke","year":"2021","unstructured":"Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, Rosenke R et al (2021) Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun 12(1):1\u20138","journal-title":"Nat Commun"},{"issue":"5","key":"5881_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/infdis\/jiab361","volume":"224","author":"R Abdelnabi","year":"2021","unstructured":"Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J (2021) Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model. J Infect Dis 224(5):749\u2013753","journal-title":"J Infect Dis"},{"key":"5881_CR40","first-page":"8","volume":"6","author":"R Cox","year":"2021","unstructured":"Cox R, Wolf J, Plemper R (2021) Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 6:8\u201311","journal-title":"Nat Microbiol"},{"key":"5881_CR41","doi-asserted-by":"crossref","unstructured":"Masyeni S, Iqhrammullah M, Frediansyah A, Nainu F, Tallei T, Emran TB et al (2022) Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2\u2014A narrative review. J Med Virol.","DOI":"10.1002\/jmv.27730"},{"issue":"1","key":"5881_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42269-022-00753-9","volume":"46","author":"S Singla","year":"2022","unstructured":"Singla S, Goyal S (2022) Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences. Bull Natl Res Cent 46(1):1\u20138","journal-title":"Bull Natl Res Cent"},{"key":"5881_CR43","doi-asserted-by":"crossref","unstructured":"Zou R, Peng L, Shu D, Zhao L, Lan J, Tan G et al (2022) Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial. Front Pharmacol. 2354","DOI":"10.3389\/fphar.2022.939573"},{"issue":"11","key":"5881_CR44","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.1002\/jmv.28011","volume":"94","author":"A De Vito","year":"2022","unstructured":"De Vito A, Colpani A, Bitti A, Zauli B, Meloni MC, Fois M et al (2022) Safety and efficacy of molnupiravir in SARS-CoV\u20102\u2010infected patients: A real\u2010life experience. J Med Virol 94(11):5582\u20135588","journal-title":"J Med Virol"},{"issue":"12","key":"5881_CR45","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/jac\/dkab318","volume":"76","author":"SH Khoo","year":"2021","unstructured":"Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R et al (2021) Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother 76(12):3286\u20133295","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"5881_CR46","doi-asserted-by":"publisher","first-page":"EVIDoa2100044","DOI":"10.1056\/EVIDoa2100044","volume":"1","author":"JR Arribas","year":"2022","unstructured":"Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R et al (2022) Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19. NEJM Evid 1(2):EVIDoa2100044","journal-title":"NEJM Evid"},{"issue":"2","key":"5881_CR47","doi-asserted-by":"publisher","first-page":"EVIDoa2100043","DOI":"10.1056\/EVIDoa2100043","volume":"1","author":"Y Caraco","year":"2022","unstructured":"Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B et al (2022) Phase 2\/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evid 1(2):EVIDoa2100043","journal-title":"NEJM Evid"},{"issue":"10373","key":"5881_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2022","unstructured":"Butler CC, Hobbs F, Gbinigie OA, Rahman NM, Hayward G, Richards DB et al (2022) Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. The Lancet 401(10373):281\u2013293","journal-title":"The Lancet"},{"key":"5881_CR49","doi-asserted-by":"crossref","unstructured":"Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. MedRxiv. 2022.","DOI":"10.1101\/2022.06.21.22276724"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-023-05881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-023-05881-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-023-05881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T04:07:01Z","timestamp":1696997221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-023-05881-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5881"],"URL":"https:\/\/doi.org\/10.1007\/s00705-023-05881-9","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"252"}}